Strong Clinical Advances In Oncology And Hepatitis Delta Will Secure Future Success

Narrative Update: Vir Biotechnology Analyst Price Targets

Analysts have lifted their average price target on Vir Biotechnology by several dollars to reflect the Astellas collaboration, encouraging VIR-5500 Phase 1 prostate cancer data, and faster than expected progress in hepatitis D, while also incorporating a higher future P/E assumption and slightly lower margin expectations into their models.

Analyst Commentary

Recent Street research on Vir Biotechnology clusters around a common theme, with multiple firms lifting price targets after the Astellas collaboration and updated VIR-5500 data. Even so, the tone is not uniform, and there are both optimistic and more cautious signals that matter for you as an investor.

Bullish Takeaways

• Bullish analysts describe the Astellas collaboration as a landmark deal for Vir's oncology ambitions, pointing to the US$335m in upfront and near term payments plus a 50/50 U.S. profit split and ex U.S. royalties as support for the valuation and funding for the pipeline.
• Several research notes highlight VIR-5500 Phase 1 data in prostate cancer as compelling and potentially best in class. They see this as reshaping Vir into a differentiated oncology company and supporting higher price targets in their models.
• Hepatitis D is repeatedly flagged as a second franchise. Some analysts suggest that the tobevibart and elebsiran combination is likely approvable, which feeds into their assumptions around future growth options beyond oncology.
• Analysts who are positive on the stock view Vir as well capitalized to execute across its dual oncology and hepatitis platforms. In their view, this reduces the execution risk they build into their valuation work.

Bearish Takeaways

• Even within positive rating and target moves, analysts are still focused on early stage data. This creates execution risk around confirming VIR-5500's profile in larger and later stage trials before any cash flows can match the higher implied valuations.
• Some research commentary ties higher target prices to specific assumptions such as increased probability of success for VIR-5500 and higher peak market share, which may prove aggressive if competitive prostate cancer treatments evolve or if subsequent data are less strong.
• The emphasis on oncology upside and a dual franchise model can raise expectations on management's ability to deliver across multiple programs at once. Any delays or mixed readouts across these programs could pressure the stock relative to the analysts' targets.
• The presence of a prior target reduction from Barclays, even without full details, is a reminder that Street views can reverse if inputs change. Investors face the risk that future revisions to clinical or partnership assumptions could reset targets again.

What’s in the News

• Vir Biotechnology closed its global collaboration and licensing agreement with Astellas for VIR-5500 following expiration of the Hart Scott Rodino waiting period, receiving a US$240m upfront payment, a US$75m equity investment at US$10.36 per share, a near term US$20m milestone and eligibility for up to an additional US$1.37b in milestones plus tiered, double digit ex U.S. royalties, with a portion of certain proceeds shared with Sanofi (Client announcement).
• Astellas and Vir entered into a global collaboration for VIR-5500 in prostate cancer, with Vir receiving US$335m in upfront and near term payments and the parties agreeing to share global development costs, 60% Astellas and 40% Vir, along with a 50/50 U.S. profit and loss split and potential ex U.S. milestones and royalties, subject at signing to customary closing conditions including Hart Scott Rodino clearance (Strategic alliances).
• Vir reported new Phase 1 data for VIR-5500 in advanced metastatic castration resistant prostate cancer, indicating that VIR-5500 monotherapy is well tolerated with promising anti tumor activity. The data were presented at the 2026 ASCO Genitourinary Cancers Symposium, and there are plans for monotherapy dose expansion in 2026 followed by pivotal Phase 3 trials in 2027, subject to typical clinical and regulatory risks (Product related announcement).
• The first patient was dosed in a monotherapy expansion cohort of the Phase 1 VIR-5500 trial in late line metastatic castration resistant prostate cancer, using a selected step up dosing regimen. The cohort is designed to track safety and measures such as PSA response rate and objective response rate, while combination dose escalation with enzalutamide continues in early line settings (Product related announcement).
• Vir completed and filed follow on equity offerings totaling up to US$350m in common stock and also entered into a share purchase agreement for 7,239,382 shares at US$10.36 per share with Astellas US LLC, alongside multiple lock up agreements on common stock, restricted stock units and stock options through April 27, 2026 (Follow on equity offerings, Private placement, End of lock up period).
• Brii Biosciences submitted a demand for arbitration against Vir related to the Collaboration, Option and License Agreement and a later letter agreement covering manufacturing transfer for the elebsiran hepatitis B program, alleging breaches and seeking specific performance on manufacturing transfer plus damages including claimed lost profits and collaboration investments (Lawsuits and legal issues).

Valuation Changes

• Fair Value: $20.78 remains unchanged, so the central valuation output of the model is stable.
• Discount Rate: risen slightly from 7.24% to 7.25%, indicating a marginally higher required return in the model.
• Revenue Growth: effectively unchanged at about 27.44%, so growth assumptions in the forecast remain consistent.
• Net Profit Margin: fallen from 14.82% to 12.92%, reflecting lower long term profitability built into the updated assumptions.
• Future P/E: increased from 174.24x to 199.97x, meaning the model now applies a higher earnings multiple to Vir Biotechnology.